Aditxt, Inc. - Common Stock (ADTX)

Aditxt, Inc. (NASDAQADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today provided an update on its subsidiary, Adimune, Inc., (“Adimune”) and its progress in advancing ADI-100, an investigational product candidate to be studied in patients with Psoriasis, Type I Diabetes (T1D) and Stiff Person Syndrome.

Aditxt (NASDAQADTX) announced that its subsidiary, Pearsanta, has engaged Dominari Securities LLC as the lead underwriter for its planned initial public offering (IPO), expected in the second half of 2025. The IPO aims to support Pearsanta’s commercialization of its Mitomic® Technology platform for early cancer detection, leveraging mitochondrial DNA biomarkers for non-invasive diagnostics. Funds raised will facilitate the U.S. launch of Laboratory Developed Tests (LDTs) and drive global expansion through regulatory approvals and distribution partnerships.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. (“Pearsanta”), has engaged Dominari Securities LLC as lead underwriter for Pearsanta’s planned initial public offering (IPO). The proposed IPO, advised by Dominari Securities, is intended to support Pearsanta’s U.S. and international commercial launch efforts and further advance its Mitomic® Technology platform for early cancer detection and diagnosis.

Aditxt (NASDAQADTX), a social innovation platform focused on advancing health innovations, will host a virtual Fireside Chat on Feb. 21, 2025, at 11:30 a.m. ET. CEO Amro Albanna will provide updates on the company’s subsidiaries, potential transactions, and pipeline advancements. The discussion will highlight Adimune, Inc.’s progress in autoimmunity treatments, including Type 1 Diabetes and Psoriasis, as well as Pearsanta’s early cancer detection program and its planned 2025 IPO. Participants can submit questions via email by Feb. 20 at 5 p.m. ET.

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced that it will host a virtual Fireside Chat on Friday, February 21, 2025, at 11:30 AM Eastern Time. The event will feature Amro Albanna, CEO of Aditxt, who will provide updates on key corporate developments, including the status of current subsidiaries, potential transactions, and notable advancements in the Company's pipeline.

Aditxt (NASDAQADTX) a social innovation platform dedicated to advancing health innovations, announced its Board of Directors has authorized management to explore an initial public offering (“IPO”) for its subsidiary, Pearsanta, Inc., in 2025. Pearsanta, a precision diagnostics company leveraging its proprietary Mitomic® Technology platform for early cancer detection, aims to use the IPO proceeds to accelerate growth and expand market presence. Aditxt CEO Amro Albanna highlighted Pearsanta’s mission to tackle the global challenge of cancer, noting the launch of the Mitomic® platform as a key milestone in advancing transformative health innovations. Pearsanta President Chris Mitton emphasized the IPO’s potential to bring its technology to the global stage, enabling faster commercialization and empowering clinicians with tools for earlier and more accurate diagnoses, positioning Pearsanta to make a meaningful impact on global healthcare outcomes.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, is pleased to announce that its Board of Directors has authorized management to explore taking its subsidiary, Pearsanta, Inc. (“Pearsanta”), public via a proposed initial public offering (“IPO”) in 2025. This decision aligns with Aditxt's mission to secure and develop transformative health innovations, positioning them for accelerated growth and broader market impact.

Aditxt (NASDAQADTX) announced that its subsidiary, Adimune, Inc., has completed all preclinical efficacy and safety studies for ADI-100, an innovative antigen-specific gene therapy for autoimmune diseases such as Type 1 Diabetes, Psoriasis, and Stiff-Person Syndrome. Preclinical results demonstrated ADI-100’s ability to restore immune tolerance without impairing the immune system’s infection or tumor-fighting capabilities, showing durable efficacy and safety in models of Type 1 Diabetes and cancer. With GMP drug substances manufactured and stability studies underway, Adimune is preparing to submit a Clinical Trial Application/Investigational New Drug application to initiate first-in-human trials. Positioned in an $84.12 billion autoimmune market, ADI-100 has the potential to replace traditional immunosuppressants and redefine treatment paradigms for autoimmune diseases.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Adimune, Inc. (“Adimune”), has successfully completed all preclinical efficacy and safety studies for its antigen-specific gene therapy, ADI-100. This achievement represents a major milestone as Adimune prepares to submit a Clinical Trial Application (CTA)/Investigational New Drug (IND) application to initiate first-in-human clinical trials for ADI-100 in the treatment of Type 1 Diabetes (T1D), Psoriasis, and in collaboration with Mayo Clinic, Stiff-Person Syndrome (SPS).

Aditxt (NASDAQADTX) provided shareholders with an update on its capital structure, disclosing details on shares issued through its Equity Line of Credit (“ELOC”) and At-the-Market (“ATM”) facility since activation. As of Nov. 7, 2024, Aditxt has sold approximately 11.9 million shares, representing 8% of the total 153 million shares traded since the ELOC and ATM initiation. The company also announced a temporary suspension of the Shelf registration statement, including ELOC and ATM, beginning November 11, pending completion of filings related to its proposed acquisitions. Moving forward, Aditxt plans to prioritize debt financing to meet capital needs, aiming to reduce equity-based dilution and maintain shareholder value.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today provided an update to its shareholders on the utilization of its Equity Line of Credit (“ELOC”) and At-the-Market (“ATM”) facility, as well as its outstanding number of shares.

Aditxt (NASDAQADTX) announced a significant advancement in its acquisition of Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF), as Appili shareholders voted overwhelmingly in favor of the proposed plan for Aditxt to acquire all Class A common shares of Appili. This positive shareholder response marks a key step in Aditxt’s strategy to expand its health innovation portfolio. Additional details and results from Appili’s special shareholder meeting are available online.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”). Shareholders of Appili overwhelmingly voted in favor of a plan of arrangement for Aditxt to acquire all issued and outstanding Class A common shares of Appili. For additional information and results of Appili’s special meeting of shareholders, please visit this link.

Aditxt (NASDAQADTX) announced today that its acquisition target, Evofem Biosciences, Inc. (OTCQB: EVFM), has secured voting agreements from key investors, solidifying their commitment to vote in favor of the upcoming merger proposal at Evofem’s Special Meeting of Stockholders. This move advances Aditxt’s planned acquisition to establish a stronghold in women’s health through Evofem. Aditxt’s CEO, Amro Albanna, highlighted that these agreements are essential for reaching quorum at the meeting and progressing with the merger, following Aditxt’s recent $2.28 million investment in Evofem as part of their amended merger agreement. Additionally, Aditxt updated stakeholders on Nasdaq compliance efforts, clarifying potential extensions to meet listing standards.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, announced today that its acquisition target, Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), has secured voting agreements with certain of its investors to ensure they will vote in favor of the merger proposal at Evofem’s upcoming Special Meeting of Stockholders (the “Special Meeting”).

Aditxt (NASDAQADTX) will host a live update and Q&A session with CEO Amro Albanna on Friday, Nov. 1, 2024, at 11:30 a.m. ET. The session will offer stakeholders insights into the company’s current initiatives, provide transaction and Nasdaq compliance updates, and include a Q&A segment addressing pre-submitted questions from investors and the public.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”), announcing that the U.S. Food and Drug Administration (“FDA”) has provided positive feedback regarding the development strategy for ATI-1801. For additional information, please visit https://finance.yahoo.com/quote/APLIF/news/.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A session with CEO Amro Albanna this Friday, November 1, 2024, at 11:30 AM ET. This update aims to connect with our stakeholders, including investors and the public, offering insights into the Company’s latest developments and will address pre-submitted questions.

Aditxt (NASDAQADTX) has appointed Sylvia Hermina to its Board of Directors, adding over 20 years of expertise in corporate governance, M&A, and shareholder relations to its leadership. As a Senior VP at Kingsdale Advisors, Hermina has played a key role in the firm’s U.S. expansion and strategic M&A initiatives. Aditxt CEO Amro Albanna highlighted the importance of Hermina’s governance experience and her alignment with the company’s growth ambitions in immune and precision health, as well as women’s health. Hermina expressed enthusiasm about contributing to Aditxt’s mission and long-term growth strategies.

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to its Board of Directors. With over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations, Ms. Hermina brings a wealth of expertise in fostering effective and impactful engagement between management teams and stakeholders.

Aditxt (NASDAQADTX) has completed a key milestone toward its acquisition of Evofem Biosciences, Inc. (OTCQB: EVFM) by purchasing $2.28 million in Evofem Series F-1 convertible preferred stock, as stipulated under their Amended and Restated Merger Agreement. This investment represents Aditxt’s final funding commitment before the merger, where Evofem, known for women’s health innovations, would become a wholly-owned subsidiary. Closing the transaction remains subject to shareholder approval, additional capital raise, and satisfaction of closing conditions. To provide further insight, Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier will join a virtual Fireside Chat on October 28, moderated by Dr. Drew Pinsky.

Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the achievement of a key milestone under the Amended and Restated Merger Agreement, as amended (the “A&R Merger Agreement”) toward completion of its intended acquisition of women’s health innovator Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM).

Aditxt (NASDAQADTX) announced a virtual fireside chat on Oct. 28, 2024, featuring Aditxt CEO Amro Albanna and Evofem Biosciences CEO Saundra Pelletier, moderated by Dr. Drew Pinsky. The discussion will provide updates on Aditxt’s acquisition of Evofem, post-acquisition strategies, and the companies’ plans to enhance women’s health care solutions. Key topics include Evofem’s FDA-approved contraceptive gel Phexxi®, the upcoming U.S. re-launch of Solosec®, and the future launch of the Mitomic Endometriosis Test (MET ). The session will explore how Aditxt’s platform supports Evofem’s growth as a multi-product women’s health franchise.

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced a virtual fireside chat set for October 28, 2024, at 11:30 AM Eastern Time. The event will be hosted by Amro Albanna, Co-Founder and CEO of Aditxt, featuring Saundra Pelletier, CEO of Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), and will be moderated by renowned physician and television personality Dr. Drew Pinsky.

Aditxt (NASDAQADTX), an innovation platform dedicated to accelerating promising health innovations, is reporting that Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF) has begun mailing its management information circular related to the company’s special meeting of shareholders, which is scheduled for next month. According to the announcement, the meeting will be held virtually on Nov. 6, 2024. An item on the meeting agenda is the proposed acquisition of by Aditxt, which Appili’s board of directors is recommending that shareholders approve.